Profile data is unavailable for this security.
About the company
Vincerx Pharma, Inc. is a clinical-stage life sciences company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s small molecule drug program includes VIP152, which is a selective, clinical-stage positive transcription elongation factor-beta/cyclin-dependent kinase 9 (PTEFb/CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. Its SMDC platform targets advanced solid tumors with optimized camptothecin, a potent cytotoxin (warhead, payload or toxophore).
- Revenue in USD (TTM)0.00
- Net income in USD-58.20m
- Incorporated2018
- Employees56.00
- LocationVincerx Pharma Inc260 Sheridan Avenue, Suite 400PALO ALTO 94306United StatesUSA
- Phone+1 (650) 800-6676
- Fax+1 (302) 655-5049
- Websitehttps://vincerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aeglea Bio Therapeutics Inc | 2.33m | -83.82m | 19.62m | 69.00 | -- | 0.3897 | -- | 8.42 | -1.03 | -1.03 | 0.0276 | 0.7698 | 0.0257 | -- | 3.91 | 33,753.63 | -92.58 | -71.18 | -114.60 | -83.92 | -- | -- | -3,598.76 | -1,414.93 | -- | -- | 0.0003 | -- | -87.57 | -14.86 | -27.38 | -- | -42.77 | -- |
| Modular Medical Inc | 0.00 | -14.88m | 19.67m | 0.00 | -- | 2.45 | -- | -- | -1.50 | -1.50 | 0.00 | 0.7339 | 0.00 | -- | -- | -- | -313.62 | -- | -- | -- | -- | -- | -- | -- | -- | -26.19 | 0.00 | -- | -- | -- | -152.55 | -- | -- | -- |
| Paranovus Entertainment Technology Ltd | 89.49m | -49.19m | 19.70m | 218.00 | -- | 0.9845 | -- | 0.2201 | -21.95 | -21.95 | 44.21 | 5.06 | 0.8516 | 54.03 | 2.89 | 410,498.40 | -51.41 | -1.15 | -61.75 | -1.34 | 4.15 | 32.41 | -60.37 | -1.26 | 3.08 | -- | 0.0285 | -- | 25.19 | 11.05 | -6,355.48 | -- | 17.03 | -- |
| Skye Bioscience Inc | 0.00 | -12.10m | 19.74m | 9.00 | -- | -- | -- | -- | -0.0244 | -0.0244 | 0.00 | -0.0066 | 0.00 | -- | -- | 0.00 | -166.29 | -295.95 | -350.36 | -- | -- | -- | -- | -- | -- | -18.94 | -- | -- | -- | -- | -29.90 | -- | 52.22 | -- |
| Lucy Scientific Discovery Inc | 0.00 | -5.89m | 20.26m | -- | -- | -- | -- | -- | -0.3617 | -0.3617 | 0.00 | -0.3532 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.68 | -- | -- | -- | -- | -23.92 | -- | -- | -- |
| Comera Life Sciences Holdings Inc | -100.00bn | -100.00bn | 20.30m | 11.00 | -- | -- | -- | -- | -- | -- | -- | 0.0603 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -27.79 | -- | -156.50 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -58.20m | 20.55m | 56.00 | -- | 0.3442 | -- | -- | -2.77 | -2.77 | 0.00 | 2.82 | 0.00 | -- | -- | 0.00 | -57.68 | -- | -69.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -136.50 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -12.34m | 20.67m | 6.00 | -- | 0.4826 | -- | -- | -0.7855 | -0.7855 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -26.68 | -67.80 | -28.54 | -82.40 | -- | -- | -- | -1,212.36 | -- | -- | 0.00 | -- | -- | -- | 53.30 | -- | -- | -- |
| DSwiss Inc | 2.30m | 180.35k | 20.69m | 9.00 | 113.64 | 100.47 | 77.34 | 9.01 | 0.0009 | 0.0009 | 0.0111 | 0.001 | 5.41 | 88.71 | 23.76 | 255,042.20 | 48.78 | -31.31 | 144.68 | -85.67 | 26.86 | 28.77 | 9.01 | -19.45 | 1.74 | 38.33 | 0.2218 | -- | 45.33 | 70.19 | 1,550.39 | -- | 2.46 | -- |
| Endexx Corp | 1.18m | -17.54m | 20.76m | -- | -- | -- | -- | 17.57 | -0.0351 | -0.0351 | 0.0024 | -0.0448 | 0.7185 | 0.382 | 7.82 | -- | -1,066.01 | -- | -- | -- | 70.09 | -- | -1,483.77 | -- | 0.0122 | -0.2837 | -- | -- | -43.43 | -- | 25.70 | -- | -- | -- |
| Zynerba Pharmaceuticals Inc | 0.00 | -35.83m | 21.23m | 28.00 | -- | 0.4024 | -- | -- | -0.866 | -0.866 | 0.00 | 1.12 | 0.00 | -- | -- | 0.00 | -47.04 | -54.20 | -54.28 | -63.35 | -- | -- | -- | -225,015.00 | -- | -81.79 | 0.00 | -- | -- | -- | 27.33 | -- | -15.38 | -- |
| Neurosense Therapeutics Ltd | -100.00bn | -100.00bn | 21.25m | 11.00 | -- | 2.71 | -- | -- | -- | -- | -- | 0.6721 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0216 | -- | -- | -- | -42.89 | -- | -- | -- |
| ABVC Biopharma Inc | 343.00k | -19.49m | 21.35m | 28.00 | -- | 3.58 | -- | 62.26 | -0.6934 | -0.6934 | 0.0116 | 0.1814 | 0.03 | 0.5916 | 1.32 | 12,250.00 | -163.89 | -- | -223.68 | -- | 93.06 | -- | -5,455.63 | -- | 0.7402 | -- | 0.2469 | -- | -26.34 | -- | -31.13 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -15.51m | 21.66m | 16.00 | -- | 2.03 | -- | -- | -0.9996 | -0.9996 | 0.00 | 0.5308 | 0.00 | -- | -- | 0.00 | -129.11 | -- | -147.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -31.52 | -- | -54.88 | -- |
| CASI Pharmaceuticals Inc | 37.01m | -27.08m | 21.71m | 168.00 | -- | 0.3594 | -- | 0.5868 | -1.97 | -1.97 | 2.69 | 4.54 | 0.2802 | 4.09 | 4.12 | 220,273.80 | -19.92 | -35.38 | -29.22 | -43.33 | 58.51 | -- | -71.10 | -337.70 | 1.68 | -- | 0.0348 | -- | 99.25 | -- | 24.09 | -- | 133.52 | -- |
Data as of Mar 21 2023. Currency figures normalised to Vincerx Pharma Inc's reporting currency: US Dollar USD
48.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Goldman Sachs & Co. LLC (Private Banking)as of 31 Jan 2023 | 2.15m | 10.14% |
| Sage Rhino Capital LLCas of 31 Dec 2022 | 1.69m | 7.96% |
| Affinity Asset Advisors LLCas of 31 Dec 2022 | 1.49m | 7.05% |
| Long Focus Capital Management LLCas of 31 Dec 2022 | 1.41m | 6.68% |
| Rock Springs Capital Management LPas of 31 Dec 2022 | 891.72k | 4.21% |
| Citadel Advisors LLCas of 31 Dec 2022 | 623.93k | 2.94% |
| Schonfeld Strategic Advisors LLCas of 31 Dec 2022 | 573.25k | 2.71% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 514.31k | 2.43% |
| Sabby Management LLCas of 31 Dec 2022 | 500.00k | 2.36% |
| Rubric Capital Management LPas of 31 Dec 2022 | 386.72k | 1.83% |
More ▼
Data from 31 Dec 2022 - 31 Dec 2022Source: FactSet Research Systems Inc.
